149 related articles for article (PubMed ID: 38170222)
1. Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma.
Li QY; Guo Q; Luo WM; Luo XY; Ji YM; Xu LQ; Guo JL; Shi RS; Li F; Lin CY; Zhang J; Ke D
Aging (Albany NY); 2024 Jan; 16(1):66-88. PubMed ID: 38170222
[TBL] [Abstract][Full Text] [Related]
2. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
3. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
4. miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Huang T; Ren K; Ding G; Yang L; Wen Y; Peng B; Wang G; Wang Z
Oncol Rep; 2020 Jun; 43(6):1906-1914. PubMed ID: 32186774
[TBL] [Abstract][Full Text] [Related]
5. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma.
Shi K; Li QY; Zhang YQ; Huang H; Ding DX; Luo WM; Zhang J; Guo Q
Aging (Albany NY); 2023 Oct; 15(20):11067-11091. PubMed ID: 37899135
[TBL] [Abstract][Full Text] [Related]
6. LINC00324 exerts tumor-promoting functions in lung adenocarcinoma via targeting miR-615-5p/AKT1 axis.
Pan ZH; Guo XQ; Shan J; Luo SX
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8333-8342. PubMed ID: 30556874
[TBL] [Abstract][Full Text] [Related]
7. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
8. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
9. The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma.
Tong S; Jiang N; Wan JH; Chen CR; Wang SH; Wu CY; Guo Q; Xiao XY; Huang H; Zhou T
BMC Cancer; 2023 Mar; 23(1):275. PubMed ID: 36973678
[TBL] [Abstract][Full Text] [Related]
10. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma.
Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW
Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
[TBL] [Abstract][Full Text] [Related]
12. MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
Lu M; Hu C; Wu F; Shu L; Pan Y; Liu X; Liu P; Ma F; Deng C; Huang M
Lung Cancer; 2020 Sep; 147():193-197. PubMed ID: 32731058
[TBL] [Abstract][Full Text] [Related]
13. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
14. GBX2, as a tumor promoter in lung adenocarcinoma, enhances cells viability, invasion and migration by regulating the AKT/ERK signaling pathway.
Wang Y; Hui J; Li R; Fu Q; Yang P; Xiao Y; Hui J
J Gene Med; 2020 Feb; 22(2):e3147. PubMed ID: 31758726
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis.
Cao L; Zhou X; Ding X; Gao D
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328193
[TBL] [Abstract][Full Text] [Related]
16. An inverse interaction between
Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
[No Abstract] [Full Text] [Related]
17. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
[TBL] [Abstract][Full Text] [Related]
18. LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.
Zhou H; Huang X; Shi W; Xu S; Chen J; Huang K; Wang Y
Cell Cycle; 2022 Jul; 21(13):1391-1405. PubMed ID: 35298351
[TBL] [Abstract][Full Text] [Related]
19. LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.
Wang L; Meng Y; Zhang QY
BMC Cancer; 2019 Apr; 19(1):293. PubMed ID: 30940109
[TBL] [Abstract][Full Text] [Related]
20. CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a.
Du H; Li Y; Sun R; Yuan Y; Sun S; Zhang Y
Thorac Cancer; 2020 Sep; 11(9):2473-2482. PubMed ID: 32648688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
